Effect of zinc supplementation on bone metabolism in male rats chronically exposed to cadmium.
The aim of the present study is to investigate, based on the rat model of moderate and relatively high human exposure to cadmium (Cd), whether zinc (Zn) supplementation may prevent Cd-induced disorders in bone metabolism. For this purpose, male Wistar rats received Cd (5 and 50mg/l) or/and Zn (30 and 60mg/l) in drinking water for 6 and 12 months. Bone densitometry and biochemical markers of bone turnover were used to assess the effects of Cd or/and Zn. Bone mineral content (BMC) and density (BMD) were measured in the femur. Serum osteocalcin (OC) and alkaline phosphatase in trabecular (bT-ALP) and cortical (bC-ALP) bone were determined as bone formation markers, and carboxy-terminal cross-linking telopeptides of type I collagen (CTX) in serum were measured as bone resorption marker. Serum concentration of calcium (Ca) and its renal handling, as well as Zn and Cd concentrations in the serum/blood, urine and femur were evaluated as well. The exposure to 5 and 50mg Cd/l (0.340+/-0.026 and 2.498+/-0.093mg Cd/kg body wt/24h, respectively), in a dose and duration dependent manner, affected bone turnover (inhibited bone formation and stimulated its resorption) and disturbed bone mineralization (decreased BMC, BMD and Zn concentration). Zn supply at the concentration of 30 and 60mg/l (1.904+/-0.123 and 3.699+/-0.213mg/kg body wt/24h, respectively) during Cd exposure influenced the Cd-induced disorders in bone metabolism. Zn administration to the Cd-exposed rats enhanced the bone ALP activity and prevented Cd-induced bone resorption, but had no statistically significant effect on BMC and BMD; however, mean values of the densitometric parameters in the rats receiving both Cd and Zn were higher than in those treated with Cd alone. Moreover, Zn supplementation at both levels of Cd exposure was found to prevent Cd accumulation in the femur and the Cd-induced decrease in bone Zn concentration. The results of the present study allow the conclusion that Zn supplementation during Cd exposure may partly protect from disorders in bone metabolism. The influence of Zn may be accompanied by its ability to prevent Cd-induced Zn deficiency and to decrease Cd accumulation in bone tissue. The findings seem to indicate that enhanced dietary intake of Zn in subjects chronically exposed to moderate and relatively high Cd levels may have a protective influence on the skeleton.
Brzóska
Malgorzata M
MM
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland. Electronic address: mmbr@poczta.onet.pl.
Rogalska
Joanna
J
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
Galażyn-Sidorczuk
Malgorzata
M
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
Jurczuk
Maria
M
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
Roszczenko
Alicja
A
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
Kulikowska-Karpińska
Elżbieta
E
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
Moniuszko-Jakoniuk
Janina
J
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
D015502:Absorptiometry, Photon; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D019256:Cadmium Chloride / Q000493:pharmacokinetics / Q000633:toxicity*; D002118:Calcium / Q000097:blood; D002712:Chlorides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D024042:Collagen Type I / Q000097:blood; D004347:Drug Interactions; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010455:Peptides / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D017967:Zinc Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D002712:Chlorides; D024042:Collagen Type I; D010455:Peptides; D017967:Zinc Compounds; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; C016837:zinc chloride; D019256:Cadmium Chloride; D002118:Calcium